Summer - United States Special Operations Command

More documents

Recommendations

Info

of CRVO neovascular complications. 14 The ability of VEGFblockers to decrease vascular permeability has also suggestedits usefulness in treating macular edema. This therapy wassuccessful in improving the vision of one patient with a nonischemicCRVO from 20/200 to 20/25 eight weeks followinginjection. Bevacizumab also offers the advantage of not causingincreases in intraocular pressure sometimes seen with intravitrealtriamcinolone injections. 13A new option for treating ischemic CRVO may behyperbaric oxygen therapy (HBOT). 15 There is a strong theoreticalbasis for HBOT to be useful in managing ischemicCRVO, and there are multiple case reports documenting successwith this treatment modality. As with central retinal arteryocclusion, there is likely a time window beyond whichHBOT is less likely to be effective, but this time window isnot well defined for CRVO. 16,17,18CONCLUSIONG6PD-deficiency is noted to affect 2.5% of militarymales, with up to 12% of the African American military population.6 Although uncertain that the CRVO experienced bythe individual described in this report was a result of his primaquinetherapy, this case still underscores the continued requirementfor routine G6PD deficiency screening indeploying military personnel and the avoidance of all potentialtriggers in patients who are G6PD-deficient. G6PD-deficientindividuals may suffer hemolytic reactions and otheradverse reactions when exposed to oxidative stressors suchas primaquine. In this case report, it may be possible that exposureto primaquine in a patient with unrecognized G6PDdeficiency may contribute to the development of CRVO.DISCLAIMERThe views, opinions, and findings contained in this reportare those of the authors and should not be construed as official orreflecting the views of the Department of Defense. There is nocopyright to be transferred as the authors are employees of the U.S.government and this report was prepared as part of their official duties.This report was approved for public release by the 75th RangerRegiment and USASOC Public Affairs Office on February 26,2008.REFERENCES1. Beutler E: G6PD deficiency. Blood 1994; 84: 3613-36.2. Cappellini M, Fiorelli G: Glucose-6-phosphate dehydrogenase deficiency.Lancet 2008; 371: 64-74.3. Frank J: Diagnosis and management of G6PD deficiency. Am FamPhysician 2005; 72: 1277-82.4. Pinna A, Carru C, Solinas G, et al: Glucose-6-phosphate dehydrogenasedeficiency in retinal vein occlusion. Invest Ophthalmol Vis Sci2007; 48: 2747-52.5. Kelley J, Opremcak E: Central retinal vein occlusion. Contemp Ophthalmol2007; 6: 1-8.6. Chinevere T, Murray C, Grant E, et al: Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. MilMed 2006; 171: 905-7.7. Lewis D, Nyska A, Potti A, et al: Hemostatic activation in a chemicallyinduced rat model of severe hemolysis and thrombosis. ThrombRes 2006; 118: 747-53.8. Prisco D, Marcucci R: Retinal vein thrombosis: Risk factors, pathogenesisand therapeutic approach. Pathophysiol Haemost Thromb2002; 32: 308-311.9. Johnson C: Arterial blood pressure and hyperviscosity in sickle celldisease. Hematol Oncol Clin North Am 2005; 19: 827-37.10. Hasan S, Elbedawi M, Castro O, et al: Retinal vein occlusion in sicklecell disease. South Med J 2004; 97: 202-4.11. Bashshur Z, Ma’luf R, Allam S: Intravitreal triamcinolone for themanagement of macular edema due to nonischemic central retinal veinocclusion. Arch Ophthalmol 2004; 122: 1137-40.12. Cekic O, Chang S, Tseng J: Intravitreal triamcinolone treatment formacular edema associated with central retinal vein occlusion andhemiretinal vein occlusion. Retina 2005; 25: 846-50.13. Spandau U, Ihioff A, Jonas J: Intraviteal bevacizumab treatment ofmacular edema due to central retinal vein occlusion. Acta OphthlamolScand 2006; 84: 555-6.14. Boyd S, Zachary I, Chakravarthy U, et al: Correlation of increasedvascular endothelial growth factor with neovascularization and permeabilityin ischemic central vein occlusion. Arch Ophthalmol 2002;120: 1644-50.15. Butler FK, Hagan C, Murphy-Lavoie H: Hyperbaric oxygen therapyand the eye. Undersea Hyperb Med 2008; 35: 333-87.16. Wright J, Franklin B, Zant E: Clinical case report: Treatment of acentral retinal vein occlusion with hyperbaric oxygen. Undersea HyperbMed 2007; 34: 315-9.17. Johnson G: A navigator with non-ischemic central retinal vein occlusionprogressing to ischemic central retinal vein occlusion. AviatSpace Environ Med 1990; 61: 962-5.18. Gismondi A, Colonna S, Micalella F, Metrangolo C: Hyperbaric oxygentherapy in thrombotic occlusion of the central retinal vein. MinervaMed 1981; 72: 1413-5.62Journal of Special Operations Medicine Volume 9, Edition 3 / Summer 09
AUTHORS*75th Ranger Regiment6420 Dawson LoopFort Benning, GA 31905russ.kotwal@us.army.milethan.miles@us.army.mil(706) 545-4230†Department of OphthalmologyNaval Operational Medicine Institute220 Hovey RoadPensacola, FL 32508frank.butler@med.navy.mil(850) 452-7720‡ Infectious Diseases ServiceBrooke Army Medical Center3851 Roger Brooke DriveFort Sam Houston, TX 78234clinton.murray@us.army.mil(210) 916-4355§1st Special Forces Group (Airborne)9190 Chapman CircleFort Lewis, WA 98433guyon.hill@us.army.mil(210) 378-9037Department of Emergency MedicineBrooke Army Medical Center3851 Roger Brooke DriveFort Sam Houston, TX 78234john.rayfield@us.army.mil(210) 916-1006Contact and Guarantor: LTC Russ S. Kotwal, MC, USAAddress: HQ, 75th Ranger Regiment, 6420 Dawson Loop, FortBenning, GA 31905Phone: Work 706/545-4545, Cell 706/366-2104Email: russ.kotwal@us.army.mil, kotwalr@soc.mil,kotwals@earthlink.netPreviously Published 63
Page 1 and 2:
Volume 9, Edition 3 / Summer 09 Jou
Page 3 and 4:
An 18D deworms a camel during a “
Page 5 and 6:
Field Evaluation and Management of
Page 7 and 8:
The circumferential anchoring strip
Page 9 and 10:
In doing so, all the skin is closed
Page 11 and 12:
NATO SOF Transformation and theDeve
Page 13 and 14:
current and future operations, thes
Page 15 and 16: sion of a physician, and limited pr
Page 17 and 18: REFERENCES1. James L. Jones, “A b
Page 19 and 20: This article is the first of two me
Page 21 and 22: Figure 4 : A Special Forces medic c
Page 23 and 24: exposure. Conversely, the customary
Page 25 and 26: 7. Ted Westmoreland. (2006). Attrib
Page 27 and 28: first three days of injury, althoug
Page 29 and 30: 9. Markgraf CG, Clifton GL, Moody M
Page 31 and 32: the only sign of OCS may be elevate
Page 33 and 34: E. The canthotomy allows for additi
Page 35 and 36: 33. Rosdeutscher, J.D. and Stradelm
Page 37 and 38: Tinnitus, a Military Epidemic:Is Hy
Page 39 and 40: The development of chronic NIHL pro
Page 41 and 42: supplied by diffusion. During expos
Page 43 and 44: similar to those of other authors,
Page 45 and 46: promising effect on tinnitus. Howev
Page 47 and 48: ADDITIONAL REFERENCESHoffmann, G; B
Page 49 and 50: et al. demonstrated that both right
Page 51 and 52: TYPICAL CHEST RADIOGRAPH FINDINGS I
Page 53 and 54: 11. Norsk P, Bonde-Petersen F, Warb
Page 55 and 56: ABSTRACTS FROM CURRENT LITERATUREMa
Page 57 and 58: tourniquet times are less than 6 ho
Page 59 and 60: tal from July 1999 to June 2002. In
Page 61 and 62: Operation Sadbhavana: Winning Heart
Page 63 and 64: CENTRAL RETINAL VEIN OCCLUSION IN A
Page 65: of the X chromosome. Notable is tha
Page 69 and 70: Casualties presenting in overt shoc
Page 71 and 72: PSYCHOLOGICAL RESILIENCE AND POSTDE
Page 73 and 74: spondents without PTSD (M = 4.6, SD
Page 75 and 76: patients, whereas the mean score of
Page 77 and 78: 29. Whealin JM, Ruzek JI, Southwick
Page 79 and 80: average, time between return from d
Page 81 and 82: ing functioning in both PTSD (Zatzi
Page 83 and 84: Editorial Comment on “Psychologic
Page 85 and 86: Blackburn’s HeadhuntersPhilip Har
Page 87 and 88: The Battle of Mogadishu:Firsthand A
Page 89 and 90: Task Force Ranger encountered enemy
Page 91 and 92: Peter J. Benson, MDCOL, USACommand
Page 93 and 94: Numerous military and civilian gove
Page 95 and 96: Anthony M. Griffay, MDCAPT, USNComm
Page 97 and 98: This is a great read that speaks di
Page 99 and 100: and twenty-eight. Rabies immune glo
Page 101 and 102: Rhett Wallace MD FAAFPLTC MC SFS DM
Page 103 and 104: LTC Craig A. Myatt, Ph.D., HQ USSOC
Page 105 and 106: LTC Bill Bosworth, DVM, USSOCOM Vet
Page 107 and 108: Europe, Mideast, Africa and SWAU.S.
Page 109 and 110: SOF and SOF Medicine Book ListWe ha
Page 111 and 112: TITLE AUTHOR ISBNCohesion, the Key
Page 113 and 114: TITLE AUTHOR ISBNI Acted from Princ
Page 115 and 116: TITLE AUTHOR ISBNRats, Lice, & Hist
Page 117 and 118:
TITLE AUTHOR ISBNThe Healer’s Roa
Page 119 and 120:
TITLE AUTHOR ISBNGuerilla warfare N
Page 121 and 122:
TITLEAUTHORBlack Eagles(Fiction)Bla
Page 123 and 124:
TITLE(Good section on Merrill’s M
Page 125 and 126:
GENERAL REFERENCESALERTS & THREATSB
Page 127 and 128:
Aviation Medicine Resources: http:/
Page 129 and 130:
LABORATORYClinical Lab Science Reso
Page 131 and 132:
A 11 year old boy whose tibia conti
Page 133 and 134:
Meet Your JSOM StaffEXECUTIVE EDITO
Page 135 and 136:
Special Forces Aidman's PledgeAs a
show all

Summer - United States Special Operations Command

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?